cyrilzakka/clinical-trials huggingface dataset:
EFFECT OF HIGH INTENSITY LASER IN PATELLOFEMORAL PAIN SYNDROME

The aim of this study is to investigate the effectiveness of high-intensity laser therapy on pain and lower extremity function in the treatment of patellofemoral pain syndrome.

Participants between the ages of 25-45 who were diagnosed with Unilateral patellofemoral pain syndrome by the doctor will be included in the study. Also positive Clarke's test and patellar compression tests will be determined as inclusion criteria. The 45 participants will be randomly divided into three groups. Both groups will receive 2 weeks (5 sessions per week) of therapy. First group patients underwent High Intensity Laser Therapy (HILT) and exercises. Second group patients will be treated by transcutaneous electrical nerve stimulation(TENS), ultrasound (US) and exercise for 10 sessions. Also In the third group patients will be treated with ultrasound (US),interferential current stimulation and exercise. All groups receive the same exercise exercise protocol including muscle strengthening and flexibility training for 12 weeks. The outcomes will be pain intensity measured by visual analog scale (VAS) , knee flexion range of motion (FROM), timed up and go test (TUG),muscle strength measured with handheld dynamometer, Pressure Pain Threshold with an algometry and functionality of knee measured by the Lower extremity functional scale and Kujala patellofemoral questionnaire. Statistical analyzes will be performed to compare amounts at baseline, immediately after treatment, and after 12 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Unilateral patellofemoral pain syndrome diagnosed by a doctor
* 25-45 years old
* pain from prolonged sitting, climbing and descending stairs, running,knee bend more than 3 months
* positive patellar compression and clarke's tests.

Exclusion Criteria:

* Previous knee pain, trauma, surgery and other joint diseases,
* Knee ligament, bursa, meniscus and synovial fold injury or dysfunction
* Osteoarthritis in the knee joint,
* Neurological problems that may affect walking
* Pregnancy
* No chronic disease
* Malignancy,
* Presence of infection
The Effect of Newspaper Reporting on COVID-19 Vaccine Hesitancy: a Randomised Controlled Trial

COVID-19 vaccine hesitancy can be observed at different rates in different countries. 1,068 people were surveyed in France and Italy to inquire about individual potential acceptance, focusing on time preferences, in a risk-return framework: having the vaccination today, in a month, and in 3 months; perceived risks of vaccination and COVID-19; and expected benefit of the vaccine. A randomized controlled trial was conducted to understand how everyday stimuli, such as fact-based news about vaccines, impact on audience acceptance of vaccination. The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract description and language, and the other used a more anecdotical description and concrete language; each group read only one of these articles. Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.

The goal of this RCT is to learn how journalistic news can affect vaccine hesitancy. 2 cohorts of unvaccinated individual, one Italian, one French. 5 arms design:

1. participants reading a fact-based newspaper article written in an abstract language
2. participants reading a fact-based newspaper article written in a more concrete language
3. participants performing abstract categorization task
4. participants performing concrete categorization task
5. control group answering questionnaire

Research questions:

i) Does a more abstract vs concrete language increase the willingness to receive the vaccine? ii) Does a more abstract vs concrete mindset increase the willingness to receive the vaccine? iii) Is a gender effect detectable?

Eligibility Criteria:
Inclusion Criteria:

unvaccinated individuals

Exclusion Criteria:

vaccinated individuals
Thermomechanical Distraction and Social Anesthesia in Interventional Radiology to Improve Patient Satisfaction

The study will prospectively analyze the analgesic and anxiolytic effects of thermomechanical stimulation (cold and vibration effects) with or without patient selected music preference during non-sedating interventional radiology procedures.

There are wide ranging influences on the perception of human pain. The perception of pain is shaped by physiology, genetic factors, prior experiences, and external ameliorating factors. Extensive research has been performed in the pediatric population utilizing distraction as a means of reducing pain, particularly during venipuncture. These methods include medications (i.e. creams, anxiolytics), behavioral distraction (i.e. music, games), cold anesthesia, and thermomechanical stimulation via a cooling/vibrating device; however, fear and anxiety associated with needle procedures does not always resolve with time or age and can result in avoidance of treatment and delays in care. Few studies have focused on the impact of non-pharmacologic anxiolytics using thermomechanical stimulation and social anesthesia (i.e. music as a form of distraction) in the adult population. Utilizing non-pharmacologic measures is one of the first steps in procedural pain management. A thermomechanical device used in the pediatric population called Buzzy (MMJ Labs, Atlanta GA) employs a battery operated, handheld plastic device with a vibrating motor and a mechanism to attach an ice pack. This is used either independently or in combination. Most reports of the device demonstrate significant pain relief, but the majority of these completed studies focused on children undergoing venous cannulation. There have been a few cited uses in adult podiatry, dermatology, and pain management. In addition, passive music based intervention have been used in cancer patients undergoing biopsy and surgery, revealing a significant pain reduction effect. The study will prospectively analyze the analgesic and anxiolytic effects of thermomechanical stimulation (cold and vibration effects) with or without patient selected music preference during non-sedating interventional radiology procedures.

Eligibility Criteria:
Inclusion Criteria:

* 18-90 years of age

Exclusion Criteria:

* prisoners, elderly, minors, pregnant women
Measurement of Gastric Secretion by MRI Under Inhibition by ProtonPump Inhibitors in Healthy Subjects & in GERD Patients

This study bases on the successfully completed project SNF 320000-112006 (EK 1152 and SwissMedic 2005dr2207e) and will document the physiological effects of inhibited gastric secretion on the volume as well as the acidity of gastric secretion by high dose proton pump inhibitors in GERD patients and healthy controls. Twelve participants in each group will be studied in a randomized, double-blind placebo controlled trial. A novel non-invasive MRI technique developed in Zurich will assess the volume of gastric secretion following the ingestion of a regular liquid meal. In addition, intragastric / esophageal pH monitoring will assess the link between volume and intragastric distribution of gastric secretion on reflux events and symptoms. In addition, the effect of gastric secretion on outcome parameters of a non-invasive stable isotope breath test for measurement of gastric emptying will be assessed.


Eligibility Criteria:
Inclusion criteria: - Healthy volunteers must have less than one episode of reflux or dyspeptic symptoms per month of no more than mild severity in the last 3 months

- Reflux patients (GERD) must have chronic symptoms (\>8 weeks) suggestive for GERD (definition and questionnaire see Appendix page 30). In addition, the initial screening manometry must show no severe esophageal dysmotility (e.g. spasm, achalasia). If in addition a pH-study has been performed the acid exposure must be \> 4.2% / 24h.

Exclusion criteria: - Age under 18 or above 65

* Pathologic underweight or overweight (BMI \< 18 or \> 30 kg/m2)
* Previous history of gastrointestinal disease or surgery (excludes appendectomy, cholecystectomy, hernia repair and anorectal disorders)
* Previous cardiorespiratory (excludes arterial hypertension), hematologic, renal, atopic, alimentary or psychiatric disease, diabetes, drug or alcohol abuse
* Patient unable to stop medication that alters gut function for 72 hours prior to the study, including anticholinergics, prokinetics, proton-pump inhibitors, non-steroidal anti-inflammatory drugs
* Positive Helicobacter pylori status on 13C-Urea breath test
* Presence of metallic implants, devices or metallic foreign bodies
* Pregnancy and lactation (female patients of child bearing age will receive a pregnancy test prior to study)
* Female volunteers without adequate contraception for the duration of the study
* Involvement in any other clinical trial during the course of this trial, nor within a period of 30 days prior to its beginning or 30 days after its completion
Four Methods of Pre-oxygenation

Four methods of preoxygenation will be compared in healthy volunteers

After informed consent, each volunteer will undergo the following techniques:

Simple mask at "flush" flow (40-60 L/min) Non-rebreather mask at 15 L/min Non-rebreather mask at 60 L/min Bag valve mask with one way exhalation valve at 15 L/min

After 3 minutes, the exhaled oxygen will be measured with an oxygen sensor

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old

Exclusion Criteria:

* Any active respiratory pathology (asthma, chronic obstructive pulmonary disease, other lung disease, smoking history more than 5 years)
* pregnant
CTEPH in Patients With Prior Pulmonary Embolism and Risk Score Validation

CTEPH-SOLUTION aims to create a risk score for the early detection of Chronic Thrombo-Embolic Pulmonary Hypertension (CTEPH) among patients with previous pulmonary embolism.

The risk score, created on retrospective data, will be validated on newly diagnosed pulmonary embolism patients.

CTEPH-SOLUTION is a multicenter observational cross-sectional and prospective study in patients with a prior and new diagnosis of pulmonary embolism.

Patients with prior pulmonary embolism will be screened at baseline with doppler echocardiography: an estimated sPAP ≥ 40 mmHg will be the indication for pulmonary hypertension detection. After 24 months from baseline, patients will be followed-up for CTEPH detection. CTEPH diagnosis will be carried out according to the current ESC/ERS guidelines.

Incident (pulmonary embolism episode at least three months before the baseline) and prevalent (pulmonary embolism episode) patients will be enrolled.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 at baseline evaluation
* Diagnosis of prior (\> 30 days from pulmonary embolism onset) or new-onset pulmonary embolism, according to the ESC guidelines on the diagnosis and management of acute pulmonary embolism

Exclusion Criteria:

* patients without pulmonary embolism diagnosis
Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol

There is some evidence that when resveratrol (a substance which is found in red grapes, peanuts and chocolate) is combined with Piperine (a substance found in pepper) it is more effective in fighting cancer. The purpose of this study is to see if resveratrol in combination with piperine is more effective than taking resveratrol alone. Since investigators don't know what dose of piperine to use in combination with resveratrol, two different doses of piperine will be studied.

Twenty-four participants, equal numbers of males and females, will receive a single dose of resveratrol (2.5 grams) without piperine, resveratrol (2.5 grams) with piperine (5 mg), or resveratrol (2.5 grams) with piperine (25 mg).


Eligibility Criteria:
Inclusion Criteria:

* Men and women age 18 to 65 years old, inclusive
* Women and men must agree to use an effective form of birth control prior to study entry and for the duration of study participation
* Willingness to abstain from foods containing resveratrol for 3 days prior to single dose administration and for 7 days after dosing. (Examples include red grapes, grape juice, peanuts, peanut butter.)
* Abstain from vitamin supplements from 2 weeks before study dosing and for 7 days following study dosing
* Eastern Cooperative Oncology Group performance status ≤ 1 (Karnofsky \> 70%)
* Participants must have normal organ and hepatic functions
* Participants must abstain from alcohol beverages 72 hours prior to dosing with the study agent, and for 7 days after dosing.

Exclusion Criteria:

* Participants who require daily medication, either prescription or over the counter (with the exception of birth control pills) will be considered ineligible. Participants who occasionally use medication (such as for pain relief or allergies) will be considered eligible; however, these participants must agree to refrain from using prn medications starting at midnight prior to the inpatient period and for seven days following dosing.
* Any cancer diagnosis within the past 5 years (except basal cell carcinoma or squamous cell carcinoma).
* Participants may not be currently receiving any other investigational agent(s) or have taken any within the past 9 months.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition of resveratrol and/or piperine.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Long-term Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy for Treatment of Lower Extremity Bowen's Disease

Er:YAG ablative fractional laser-assisted methyl aminolevulinate photodynamic therapy (AFL-PDT) has shown significantly higher efficacy and a lower recurrence rate at 12 months than methyl aminolevulinate photodynamic therapy (MAL-PDT) for treatment of Bowen's disease (BD). However, long-term follow up data are not available.

To compare the long-term efficacy and recurrence rates of AFL-PDT and standard MAL-PDT for the treatment of lower extremity BD.

Eligibility Criteria:
Inclusion Criteria:

* •Patients aged 18 years or more who diagnosed as bowen's disease

Exclusion Criteria:

* pregnancy or lactation
* active systemic infectious disease
* other inflammatory, infectious, or neoplastic skin diseases in the treated area
* allergy to MAL,other topical photosensitizers, or excipients of the cream
* history of photosensitivity
* use of immunosuppressive or photosensitizing drugs
* participation in any other investigational study in the preceding 30 days
* history or indicators of poor compliance
* Histological findings of acantholysis, desmoplasia, perineural or lymphovascular invasion, and echographic features of regional lymph node metastasis were the disease-specific exclusion criteria
The Effect of Non Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD) Symptoms - Proof of Concept Study

The aims of the study: To evaluate whether the use of a specific TENS technology can improve GERD symptoms and esophageal acid exposure.


Eligibility Criteria:
Inclusion Criteria:

* at least 3 episodes of heartburn and/or regurgitation in a week for at least 3 months.
* evidence for an abnormal esophagal acid exposure on impedance-pH monitoring (tested in the last 2 years off PPI)

Exclusion Criteria:

* gastric or esophagal surgery
* active peptic ulcer disease
* malignancy
* pregnancy
* uncontrolled diabetes mellitus
* severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker/defibrillator
* allergy to adhesives/patches
* severe pulmonary disease
* obesity (BMI\>30)
Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia

The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose and mode of administration of the medication.

RECONNECT-S BETA

Eligibility Criteria:
Inclusion Criteria:

* Meet the diagnostic criteria for schizophrenia stated in The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria.
* Subject is hospitalised due to an acute psychotic episode.
* Ability of the subject to understand and comply with the requirements of the study, as judged by the investigator.

Exclusion Criteria:

* Current participation in any clinical trial.
* Previous enrolment in the present NIS (in case of recurrence occurred during the enrolment period).
Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)

This study is designed to report 3-year result of triple therapy of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation for intractable diabetic macular edema.

Previously author reported 1-year result(Am J Ophthalmol. 2007 Dec;144(6):878-885. Epub 2007 Oct 15.).


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of diabetes mellitus
* intractable diffuse DME (diffuse DME which did not respond to or recurred after the previous IVTA and/or macular focal laser photocoagulation)
* central subfield macular thickness (CST) greater than 250μm

Exclusion Criteria:

* presence of vitreomacular traction
* a prior history of treatment for the DME within 3 months or vitreoretinal surgery
Performance Evaluation of In-Vitro Diagnostic Device

This is an interim report for POC testing of skyla Clinical Chemistry Analyzer and four skyla Test Systems (ALB, BUN, GLU, and TP). The analyses are performed with skyla Clinical Chemistry Analyzer.

Analyte Principle:

Albumin (ALB) - Dye-Binding BCG

Blood urea nitrogen (BUN) - Urease with GLDH (coupled enzyme)

Glucose (GLU) - Hexokinase, Colorimetry

Total Protein (TP) - Biuret


Eligibility Criteria:
Inclusion Criteria:

* You must be an adult over 20 years of age and weigh over 50 kg to be eligible to participate in the study.

Exclusion Criteria:

* You may not participate in this study if you do not meet the above inclusion criteria.
Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis

This study describes the development and validation of a deep learning prediction model, which extracts deep learning features from preoperative enhanced CT scans and analyzes postoperative pathological specimens of pancreatic cancer patients. The aim is to predict patient prognosis and response to chemotherapy treatment.

This study retrospectively collected enhanced CT scan data, pathological paraffin blocks, and clinical data from pancreatic cancer patients who underwent surgery at multiple centers between March 2013 and May 2024. The pathological paraffin blocks were stained using immunohistochemistry for prognostic immune microenvironment markers, and patients were classified based on these results. Subsequently, deep learning features were extracted from enhanced CT scans, and a multimodal prediction model was constructed using imaging features and clinical information. The model's performance was evaluated using metrics including area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with pancreatic cancer, diagnosed through pathology;
2. Patients underwent surgery and received adjuvant chemotherapy after surgery.

Exclusion Criteria:

1. Missing or inadequate quality of CT,
2. Incomplete clinical or pathological data.
3. Multiple primary malignancies;
4. History of malignancy.
Effect of Protein and Retinol on Alcohol-induced FGF21

The aims of this study are two-fold. First to investigate the influence of protein on the FGF21 response induced by alcohol, and second to investigate the influence of retinol on FGF21 concentrations and the FGF21 response induced by alcohol. Exploratory, and in order to investigate mechanisms behind the potential influence on alcohol-induced FGF21 response from protein or retinol intake, plasma glucose, insulin, glucagon, ethanol, acetaldehyde, acetate, retinol, retinoic acid, as well as subjective rating of appetite, will be measured.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent
* Healthy men and women
* Age between 18 and 50 years
* Body mass index (BMI) between 20 and 27 kg/m2

Exclusion Criteria:

* Chronic diseases or significant health problems that are disruptive for participation in the study (as judged by the principal investigator/clinical responsible)
* Use, currently or within the previous 3 months, of medication that has the potential of affecting any of the blood parameters assessed in the study (as judged by the investigators)
* Blood donation within the last 3 months or during the study period
* Regular smoking or other nicotine use (electronic cigarettes, gum, snus, etc.) or nicotine cessation within the past 3 months.
* Currently dieting or having lost/gained a significant amount of weight (±3 kg) in the previous 3 months
* Women who are pregnant, breast-feeding or have the intention of becoming pregnant during the study period
* Food allergies or food intolerance relevant for the study (judged by the investigators)
* Substance abuse (alcohol and/or drugs) within the last 12 months
* Average weekly alcohol intake above the recommendations from the Danish Health and Medicines Authority (10 standard units per week)
* Taking dietary supplements containing vitamin A during the past 3 months
* Simultaneous participation in other clinical studies that can interfere with the current study
* Inability, physically or mentally, to comply with the procedures required by the study protocol
Treatment of Myocardial Infarction With Bone Marrow Derived Stem Cells

The aim of the study is to investigate whether infusion of autologous bone marrow derived stem cells can improve cardiac function in the aftermath of a myocardial infarction.

Primary coronary intervention within a few hours of a myocardial infarction has greatly reduced mortality as well as the risk of developing chronic heart failure. There are though still a large number of patients that develop symptoms of heart failure in the form of fatigue and breathlessness with physical exertion in spite of medical treatment. With the advance in stem cell technology there is now hope for the possibility of regenerating/repairing dead myocardial tissue, hence improving cardiac function.

The current study is a pilot study that is going to precede a later double blinded randomized study. The aim of the study is to evaluate patient safety, optimize procedures, and to be used in power calculation in the design of the following study.

Eligibility Criteria:
Inclusion Criteria:

* Chestpain
* Troponin T, \> 0,1ng/ml
* Succesfull revascularization of culprit lesion with PCI.
* No more than stenosis of 2 major epicardiel coronary arteries.

Exclusion Criteria:

* Cardiogenic shock
* Known LVEF\<45%
* Cardiomyopathy
* Atrialfibrillation or fluctuation
* Takyarytmia
* Infection
* Chronic inflammatory disease